Relapses in paucibacillary leprosy after MDT--a clinical study.

Area of Science:

• Dermatology
• Infectious Diseases
• Public Health

Background:

• Leprosy remains a global health concern, necessitating effective treatment strategies.
• Multidrug therapy (MDT) is the standard treatment for leprosy, but relapse can occur.
• Understanding relapse patterns in paucibacillary leprosy is crucial for optimizing patient outcomes.

Purpose of the Study:

• To determine the incidence and clinical characteristics of relapses in paucibacillary leprosy patients after completing multidrug therapy (MDT).
• To identify factors associated with leprosy relapse after MDT.
• To inform clinical practice regarding leprosy treatment duration and follow-up.

Main Methods:

• A field-based study involving 1509 paucibacillary leprosy patients who received at least 6 doses of MDT (WHO regimen).
• Prospective follow-up to monitor for relapses and record clinical features.
• Statistical analysis to calculate relapse rates and identify risk factors.

Main Results:

• A relapse rate of 5.63% (17.5 per 1000 person-years) was observed among paucibacillary leprosy patients post-MDT.
• Seventy-nine percent of relapses presented with skin lesions, and 12 cases showed reversal reactions.
• Higher relapse rates were noted in borderline cases and those with more initial lesions. Extended dapsone therapy post-MDT was associated with lower relapse rates.
• Most relapses (74%) were detected between 7 and 24 months after treatment completion.

Conclusions:

• Standardized clinical criteria for leprosy relapse diagnosis are needed.
• Individualizing leprosy treatment duration, rather than adhering to fixed MDT regimens, may improve cure rates and reduce relapses.
• Further research into optimal treatment strategies and long-term follow-up for paucibacillary leprosy is warranted.